Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable‐risk prostate cancer
Cancer Medicine · 2023
DOI: 10.1002/cam4.5650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Da Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Watchful Waiting, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Active surveillance/watchful waiting (AS/WW) is feasible and effective for favorable‐risk prostate cancer (PCa). Understanding socioeconomic determinants of AS/WW may help determine the target population for social support and improve cancer‐related survival.
Methods
The Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database 18 Registries identified 229,428 adult men diagnosed with primary localized PCa (clinical T1‐T2c, N0M0) during a median follow‐up of 45 months between 2010 and 2016. Socioeconomic determinants included socioeconomic status (SES) tertiles, marital status (unmarried vs married), and residency (urban vs rural). Multivariable logistic regression and Cox models determined the adjusted odds ratios (aOR) for AS/WW utilization, and adjusted hazard ratio (aHR) for cancer‐specific survival (CSS) and overall survival (OS). The extent of missing data was evaluated by multiple imputation. Sensitivity analyses were performed in multiple imputation datasets.
Results
Unmarried patients were more likely to receive AS/WW in low‐risk group (aOR, 1.20 [95%CI, 1.12–1.28]; p < 0.001) and favorable intermediate‐risk group (aOR, 1.41 [95%CI, 1.26–1.59]; p < 0.001) than married patients. Urban patients had 0.77‐fold lower likelihood of AS/WW than rural patients in low‐risk group (95% CI, 0.68–0.87; p < 0.001), but not in favorable intermediate‐risk groups. Among patients undertaking AS/WW, a significantly worse OS was observed among unmarried patients comparing to married group (aHR, 1.98 [95% CI, 1.50–2.60]; p < 0.001), and patients with high SES had better CSS than low group (aHR, 0.08 [95%CI, 0.01–0.69]; p = 0.02). No significant survival difference was found between urban and rural patients. Conclusions and Relevance Unmarried or urban patients had significantly higher rates of AS/WW. The utilization and efficacy of conservative management were affected by socioeconomic factors, which might serve as a barrier of treatment decision‐making and targeted a population in need of social support.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
ORCID-Profile: Da Huang, Jingyi Huang, Danfeng Xu, Rong Na
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, D., Ruan, X., Huang, J., Zhang, N., Jiang, G., Gao, Y., Xu, D., & Na, R. (2023). Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable‐risk prostate cancer. Cancer Medicine. https://doi.org/10.1002/cam4.5650
Vancouver
Huang D, Ruan X, Huang J, Zhang N, Jiang G, Gao Y, et al. Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable‐risk prostate cancer. Cancer Medicine. 2023. doi:10.1002/cam4.5650
BibTeX
@article{Huang2023,
author = {Huang, Da and Ruan, Xiaohao and Huang, Jingyi and Zhang, Ning and Jiang, Guangliang and Gao, Yi and Xu, Danfeng and Na, Rong},
title = {Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable‐risk prostate cancer},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5650}
}
EUVIMED